BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides - Sakamoto, Kei; Matsuki, Shunji; Matsuguma, Kyoko; Yoshihara, Tatsuya; Uchida, Naoki; Azuma, Fumihiko; Russell, Muir; Hughes, Glen; Haeberlein, Samantha Budd; Alexander, Robert C; Eketjäll, Susanna; Kugler, Alan R (Journal of clinical pharmacology, 2017)
Keywords: Adult; Aged; Alzheimer Disease - drug therapy; Amyloid beta-Peptides - metabolism; Amyloid beta-Protein Precursor - metabolism; Amyloid Precursor Protein Secretases - antagonists & inhibitors; Amyloid Precursor Protein Secretases - metabolism; Asian Continental Ancestry Group; Aspartic Acid Endopeptidases - antagonists & inhibitors; Brain - metabolism; Cerebrospinal Fluid - metabolism; Double-Blind Method; Female; Half-Life; Healthy Volunteers; Humans; Imidazoles - therapeutic use; Male; Middle Aged; Peptide Fragments - metabolism; Plasma - metabolism; Spiro Compounds - therapeutic use; Young Adult; Alzheimer disease; amyloid-β peptides; lanabecestat, AZD3293; clinical trials; BACE1 protein-human; Japanese; cerebrospinal fluid proteins